Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) shares were down 3.4% during mid-day trading on Monday . The stock traded as low as $9.30 and last traded at $9.30. Approximately 50,727 shares traded hands during mid-day trading, a decline of 93% from the average daily volume of 772,685 shares. The stock had previously closed at $9.63.
Wall Street Analyst Weigh In
A number of equities analysts have recently weighed in on the stock. Oppenheimer lowered their price target on shares of Oric Pharmaceuticals from $15.00 to $12.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 6th. HC Wainwright reaffirmed a "buy" rating and set a $21.00 price target on shares of Oric Pharmaceuticals in a research note on Monday, May 5th. JPMorgan Chase & Co. upped their price target on shares of Oric Pharmaceuticals from $21.00 to $22.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. Guggenheim reaffirmed a "buy" rating on shares of Oric Pharmaceuticals in a research note on Wednesday, February 26th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Oric Pharmaceuticals in a research note on Tuesday, May 6th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Oric Pharmaceuticals has an average rating of "Buy" and an average target price of $19.17.
View Our Latest Analysis on Oric Pharmaceuticals
Oric Pharmaceuticals Trading Up 2.1%
The stock has a market capitalization of $785.73 million, a price-to-earnings ratio of -4.93 and a beta of 1.49. The stock's 50 day moving average is $6.53 and its 200 day moving average is $7.69.
Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The company reported ($0.42) EPS for the quarter, beating analysts' consensus estimates of ($0.51) by $0.09. On average, sell-side analysts anticipate that Oric Pharmaceuticals, Inc. will post -2.17 EPS for the current year.
Insider Activity at Oric Pharmaceuticals
In related news, CFO Dominic Piscitelli sold 2,600 shares of the stock in a transaction dated Friday, June 6th. The shares were sold at an average price of $10.01, for a total value of $26,026.00. Following the sale, the chief financial officer now directly owns 104,164 shares of the company's stock, valued at approximately $1,042,681.64. This represents a 2.44% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last three months, insiders have sold 6,500 shares of company stock valued at $65,056. Insiders own 6.82% of the company's stock.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Invesco Ltd. lifted its holdings in Oric Pharmaceuticals by 8.5% in the 4th quarter. Invesco Ltd. now owns 23,958 shares of the company's stock valued at $193,000 after purchasing an additional 1,876 shares in the last quarter. PNC Financial Services Group Inc. lifted its holdings in Oric Pharmaceuticals by 22.9% in the 4th quarter. PNC Financial Services Group Inc. now owns 13,517 shares of the company's stock valued at $109,000 after purchasing an additional 2,520 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Oric Pharmaceuticals by 8.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,201 shares of the company's stock valued at $226,000 after purchasing an additional 3,131 shares in the last quarter. Swiss National Bank lifted its holdings in Oric Pharmaceuticals by 5.4% in the 4th quarter. Swiss National Bank now owns 62,400 shares of the company's stock valued at $504,000 after purchasing an additional 3,200 shares in the last quarter. Finally, Rhumbline Advisers lifted its holdings in Oric Pharmaceuticals by 4.6% in the 4th quarter. Rhumbline Advisers now owns 93,319 shares of the company's stock valued at $753,000 after purchasing an additional 4,072 shares in the last quarter. 95.05% of the stock is currently owned by hedge funds and other institutional investors.
Oric Pharmaceuticals Company Profile
(
Get Free Report)
ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.
Recommended Stories
Before you consider Oric Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oric Pharmaceuticals wasn't on the list.
While Oric Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
